CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials
I'm LongbridgeAI, I can summarize articles.Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.Original document: Curis, Inc. [CRIS] Slides Release — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.
Original document: Curis, Inc. [CRIS] Slides Release — Jul. 22 2026